Thalys Medical Technology Group Corporation (SHA:603716)

Market Cap	3.54B -29.4%
Revenue (ttm)	709.31M -43.2%
Net Income	-176.05M
EPS	-0.81
Shares Out	221.81M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	20,075,495
Open	16.45
Previous Close	16.59
Day's Range	14.93 - 16.59
52-Week Range	12.92 - 31.86
Beta	0.33
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 29, 2026

About SHA:603716

Thalys Medical Technology Group Corporation provides medical integrated operation and management services in China. The company offers fully automated immunofluorescence analyzer; coagulation reagent; COVID-19 test kit; line blot1 fully automated immunoblotting instrument; and flow products. It also provides automated coagulation analyzer; automated immunoassay system; automated biochemical analysis system; automated chemiluminescence immunoassay system; and blood analyzer. The company was formerly known as Thalys Medical Technology Inc. and ch...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2004
• Employees: 1,045
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603716

Financial Performance

In 2025, SHA:603716's revenue was 1.08 billion, a decrease of -40.52% compared to the previous year's 1.81 billion. Losses were -207.28 million, -0.93% less than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 2, 2026

Data Sources Report a data error